Core Viewpoint - Shanghai Sanyou Medical Instrument Co., Ltd. has signed a strategic cooperation and distribution agreement with CGBio Co., Ltd. to obtain exclusive distribution rights for the Novosis product in mainland China, which is expected to enhance the company's product line and competitive strength in the orthopedic biomaterials sector [2][4][20]. Agreement Overview - The agreement grants Sanyou Medical exclusive and non-transferable rights to procure, import, market, distribute, sell, promote, and conduct other commercial activities related to the Novosis product in mainland China for a period of six years, starting from the date the product receives medical device registration from the National Medical Products Administration of China [2][9][10]. Product Details - Novosis is a biomaterial product containing recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, designed for synthetic bone grafting. It is produced using genetically engineered E. coli and is packaged with a disposable syringe and needle [3][11][19]. - The product is known for its strong osteoconductive and osteoinductive properties, promoting the formation of new bone and cartilage, and is widely used in various surgical repairs, including spinal fusion and trauma [12][20]. Impact on the Company - The exclusive distribution rights for Novosis will enrich Sanyou Medical's product offerings and enhance its position in the orthopedic biomaterials market, providing comprehensive surgical solutions for patients and doctors, which is expected to positively impact the company's operations [4][20]. - Sanyou Medical is recognized as a leading company in the development, production, and sales of orthopedic implant consumables, with strong market sales channels and a rich customer base [18]. Partner Company Overview - CGBio Co., Ltd. is a South Korean company specializing in the research, production, and sales of medical device biomaterials, with significant expertise in various core technologies related to tissue regeneration and implant design [18].

Core Viewpoint - The company has signed a strategic cooperation and distribution agreement with CGBio, granting exclusive rights to distribute Novosis products in mainland China, which is expected to enhance its competitive strength in the orthopedic biomaterials sector [1][3]. Group 1: Agreement Details - The agreement was signed on December 2, 2025, and grants the company exclusive, non-transferable rights for procurement, import, marketing, distribution, sales, promotion, and other commercialization activities for Novosis products in mainland China [1]. - The authorization is valid for six years from the date the products receive medical device registration from the National Medical Products Administration of China [1]. Group 2: Product Information - Novosis is a synthetic bone graft material composed of recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, packaged with a disposable syringe and needle [2]. - The product is produced through genetic engineering from human rhBMP-2 cDNA and is designed to promote new bone formation with strong osteoconductive and osteoinductive properties [2]. - It is widely used in various surgical repair and reconstruction applications, including spinal fusion, limb trauma, and oral surgery [2]. Group 3: Strategic Impact - Acquiring exclusive distribution rights for Novosis products will enrich the company's product line and enhance its positioning in the orthopedic biomaterials market, providing comprehensive surgical solutions for patients and doctors [3]. - This move is expected to positively impact the company's operations and overall competitiveness in the industry [3].

Core Viewpoint - The company has signed a strategic cooperation and distribution agreement with CGBio, granting exclusive rights to distribute Novosis products in mainland China for six years after obtaining regulatory approval [1][3]. Group 1: Agreement Details - The agreement allows the company to engage in procurement, import, marketing, distribution, sales, promotion, and other commercialization activities for Novosis products in mainland China [1]. - The exclusivity of the rights is contingent upon the product receiving a medical device registration certificate from the Chinese National Medical Products Administration [1]. Group 2: Product Information - Novosis is a synthetic bone graft material composed of recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, packaged with a disposable syringe and needle [2]. - The product is produced using genetically engineered E. coli to efficiently produce rhBMP-2, which promotes new bone formation and has strong osteoconductive and osteoinductive properties [2]. - rhBMP-2 is widely used in various surgical repair and reconstruction applications, including spinal fusion, limb trauma, and oral surgery [2]. Group 3: Strategic Impact - Acquiring exclusive distribution rights for Novosis will enhance the company's product line and strengthen its position in the orthopedic biomaterials sector, providing comprehensive surgical solutions for patients and doctors [3]. - This development is expected to positively impact the company's overall competitiveness and operational performance [3].

Core Viewpoint - Company signed a strategic cooperation and distribution agreement with CGBIO for exclusive rights to market and distribute Novosis products in mainland China, enhancing its competitive position in the orthopedic biomaterials sector [1][2] Group 1: Agreement Details - The agreement grants the company exclusive, non-transferable rights for procurement, import, marketing, distribution, sales, promotion, and other commercialization activities for Novosis products in mainland China [1] - The authorization is valid for six years from the date the products receive medical device registration from the Chinese regulatory authority [1] Group 2: Product Information - Novosis is a synthetic bone graft material composed of recombinant human bone morphogenetic protein BMP-2 and hydroxyapatite ceramic, packaged with a disposable syringe and needle [1] - The product is produced using genetically engineered E. coli to efficiently manufacture rhBMP-2, which promotes new bone formation and has strong osteoconductive and osteoinductive properties [1] Group 3: Market Impact - The acquisition of exclusive distribution rights for Novosis will enrich the company's product line and enhance its offerings in the orthopedic biomaterials field [2] - This development is expected to provide comprehensive surgical solutions for patients and doctors, positively impacting the company's operations and overall competitiveness [2]

Core Viewpoint - The company has signed a strategic cooperation and distribution agreement with a South Korean firm, obtaining exclusive and non-transferable distribution rights for Novosis products in mainland China, which will enhance its product line in the orthopedic biomaterials sector [1] Group 1: Agreement Details - The agreement was signed on December 2, 2025, with a validity period of six years from the date the product receives medical device registration from the Chinese regulatory authority [1] - Novosis is a recombinant human bone morphogenetic protein BMP-2 biomaterial product that promotes new bone formation [1] Group 2: Impact on Company - This collaboration will enrich the company's product offerings and improve its positioning in the orthopedic biomaterials market [1] - However, there is uncertainty regarding the product's registration approval and market launch, making it difficult to predict the specific impact on the company's performance [1]